These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

873 related items for PubMed ID: 18338814

  • 1. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D, Tyldesley S, Pickles T, Prostate Cohort Outcomes Initiative.
    Cancer; 2008 May 01; 112(9):1941-8. PubMed ID: 18338814
    [Abstract] [Full Text] [Related]

  • 2. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
    Palma D, Tyldesley S, Blood P, Liu M, Morris J, Pickles T, Prostate Cohort Outcomes Initiative.
    Int J Radiat Oncol Biol Phys; 2007 Apr 01; 67(5):1425-9. PubMed ID: 17394943
    [Abstract] [Full Text] [Related]

  • 3. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality.
    Nguyen PL, Chen MH, Renshaw AA, Sussman B, D'Amico AV.
    Urology; 2007 Aug 01; 70(2):288-93. PubMed ID: 17826491
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV.
    Cancer; 2006 Dec 01; 107(11):2597-603. PubMed ID: 17039498
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.
    Cancer; 2008 Mar 15; 112(6):1247-53. PubMed ID: 18293426
    [Abstract] [Full Text] [Related]

  • 8. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):36-9. PubMed ID: 19233568
    [Abstract] [Full Text] [Related]

  • 9. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK, Levy LB, Cheung R, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):456-62. PubMed ID: 15927415
    [Abstract] [Full Text] [Related]

  • 10. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.
    J Natl Cancer Inst; 2007 Oct 17; 99(20):1516-24. PubMed ID: 17925537
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH.
    Cancer; 2007 Apr 01; 109(7):1290-5. PubMed ID: 17315162
    [Abstract] [Full Text] [Related]

  • 13. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D'Amico AV.
    Cancer; 2007 Apr 15; 109(8):1493-8. PubMed ID: 17340594
    [Abstract] [Full Text] [Related]

  • 14. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
    Yu HH, Song DY, Tsai YY, Thompson T, Frassica DA, DeWeese TL.
    Urology; 2007 Jul 15; 70(1):111-6. PubMed ID: 17656219
    [Abstract] [Full Text] [Related]

  • 15. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA.
    Cancer; 2009 Oct 01; 115(19):4470-6. PubMed ID: 19637339
    [Abstract] [Full Text] [Related]

  • 16. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
    D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW.
    Cancer; 2007 Jul 01; 110(1):56-61. PubMed ID: 17530618
    [Abstract] [Full Text] [Related]

  • 17. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP, Deibl M, Strasak A, Bektic J, Pelzer A, Steiner H, Spranger R, Fritsche G, Bartsch G, Horninger W.
    Urology; 2006 Nov 01; 68(5):1067-71. PubMed ID: 17095070
    [Abstract] [Full Text] [Related]

  • 18. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y, Prostate Cancer Study Group.
    Int J Urol; 2004 May 01; 11(5):295-303. PubMed ID: 15147545
    [Abstract] [Full Text] [Related]

  • 19. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR, Presti JC, Brooks JD, Gill H, Spiotto MT.
    Int J Radiat Oncol Biol Phys; 2008 Apr 01; 70(5):1472-7. PubMed ID: 17935902
    [Abstract] [Full Text] [Related]

  • 20. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.
    Urology; 2008 Jan 01; 71(1):136-40. PubMed ID: 18242382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.